FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

7 REMS Updates in July, August

[ Price : $8.95]

FDA releases a summary of changes to seven REMS shown on the REMS Web site in July and August.

Novartis Plans BLA for Arzerra in MS

[ Price : $8.95]

Novartis says it will file a BLA and seek other global approvals for its leukemia drug Arzerra (ofatumumab) and its use in treatin...

CDRH Seeks to Fill Vacancies on Device Panels

[ Price : $8.95]

Federal Register notice: FDA requests nominations for voting members to serve on CDRHs Device Good Manufacturing Practice Advisory...

Docket No. on Pediatric Rare Disease Corrected

[ Price : $8.95]

Federal Register notice: FDA corrects the docket number in a 12/2017 notice entitled Pediatric Rare Diseases--A Collaborative Appr...

9 Bulk Drugs Proposed for Compounding Exclusion

[ Price : $8.95]

Federal Register notice: FDA seeks comments on nine bulk drug substances that it is proposing not to allow outsourcing facilities ...

Concept Medical Breakthrough Status on MagicTouch

[ Price : $8.95]

FDA grants Concept Medical a breakthrough device designation for MagicTouch AVF, a sirolimus drug-coated balloon catheter for trea...

Akari Therapeutics Gains Orphan Status for Nomacopan

[ Price : $8.95]

FDA grants Akari Therapeutics an orphan drug designation for nomacopan and its use in treating hematopoietic stem cell transplanta...

Regulatory Review Period for Pumas Nerlynx

[ Price : $8.95]

Federal Register notice: FDA determines the regulatory review period for patent extension purposes for Puma Bios Nerlynx (neratini...

Could Sharpless Get Trumped by HHS Asst. Secretary?

[ Price : $8.95]

The Trump Administration mulls FDA acting commissioner Ned Sharpless time at the agency, and without a nomination to move him into...

FDA Seeks Move to New Duodenoscopes

[ Price : $8.95]

An FDA safety alert recommends that healthcare providers transition to duodenoscopes with innovative designs that are more safe an...